Morphine IR & ER
ID: SPE2D2-25-R-0012Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/78c53b0ef7c343869d7b42f09056d828/view
Timeline
  1. 1
    Posted Apr 7, 2025, 12:00 AM UTC
  2. 2
    Updated Apr 7, 2025, 12:00 AM UTC
  3. 3
    Due Not available
Description

The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Morphine Immediate Release (IR) and Extended Release (ER) Tablets. The procurement will include Morphine IR in 15MG and 30MG in 100 count bottles, as well as Morphine ER in 15MG, 30MG, and 60MG in 100 count bottles, aimed at establishing a national supply source for the Department of Defense, Indian Health Service, and Bureau of Prisons customers. This contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and it will be solicited as a commercial item under FAR part 12. Interested parties should contact Christopher Newman at 445-737-7371 or christopher.newman@dla.mil for inquiries, and they are encouraged to monitor the DLA Bid Board System (DIBBS) and Sam.Gov for updates, with the projected solicitation date set for April 2025.

Files
No associated files provided.
Lifecycle
Title
Type
Morphine IR & ER
Currently viewing
Presolicitation
Similar Opportunities
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Duloxetine HCL DR Capsules
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules, which includes various dosages and packaging options. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in April 2025. Interested parties should direct inquiries to Christopher Newman at christopher.newman@dla.mil or 445-737-7371, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
Solifenacin
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Solifenacin, specifically 5MG and 10MG tablets in 30 and 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Indian Health Service, and Bureau of Prisons through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should direct inquiries to Jayne Do at jayne.do@dla.mil, with the solicitation anticipated to be posted in April 2025 on the DLA Bid Board System and SAM.gov.
Metformin HCL
Buyer not available
Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
Ibuprofen 400MG/600MG/800MG Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
Valsartan/Hydrochlorothiazide Tablets
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Valsartan/Hydrochlorothiazide Tablets, which includes various dosages in 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are essential for treating hypertension and heart failure, and will serve customers including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in May 2025. Interested parties can reach out to Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for inquiries, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Rizatriptan Benzoate
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
Pyridostigmine Bromide Tablets
Buyer not available
The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Pyridostigmine Bromide Tablets (PB Tabs), specifically the USP 30 MG formulation, in compliance with FDA specifications. The procurement involves an estimated annual requirement of 27,000 packages, with each package containing 210 individually sealed tablets, and deliveries will be made to the Defense Distribution Center in Norfolk, VA. Pyridostigmine Bromide Tablets are critical for military use, and the contract will include a base year with four one-year option periods, allowing for adjustments based on service requirements. Interested vendors should submit their responses electronically to Contracting Specialist Rosbert Jones at rosbert.jones@dla.mil, ensuring all information remains confidential as per federal regulations.
Budesonide ER Capsules
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Budesonide ER 3MG Capsules, as outlined in Solicitation No. SPE2D225R0008. This solicitation requires electronic submission of offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) and includes a comprehensive Statement of Work detailing contract obligations such as delivery schedules, product registration, and compliance with federal acquisition regulations. The procurement of these pharmaceutical products is critical for supporting military health needs, ensuring that service members have access to necessary medications. Interested vendors should direct inquiries to Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil, with proposals due by the specified deadline in the solicitation document.